

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276

| | |
|-------------------|---------------------------------|
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 70 participants |

Key Eligibility Criteria

Inclusion (35)

- Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable mutation as defined in EAY191
 - Patients must have a HER2 amplified solid tumor except breast cancer.
 - If IHC is 0 or 1+, patient (pt) is NOT ELIGIBLE regardless of in situ hybridization (ISH)/FISH or next generation sequencing (NGS) status
 - If IHC is 3+, pt IS ELIGIBLE regardless of ISH/FISH or NGS status
 - If IHC is 2+, ISH/FISH OR NGS must be positive for the patient to be ELIGIBLE. Otherwise, pt is NOT ELIGIBLE
- ... and 30 more (see full listing online)

Locations (182 total)

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
... and 179 more locations